[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Carrabin N, Mithieux F, Meeus P, Trédan O, Guastalla JP, Bachelot T, Labidi SI, Treilleux I, Rivoire M, Ray-Coquard I: Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull Cancer; 2010 Apr;97(4):E23-32
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.
  • OBJECTIVE: To assess the feasibility and efficacy of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) without adjuvant chemotherapy for relapsed or persistent advanced ovarian cancer.
  • METHODS: This observational study included stage IIIC ovarian cancer patients due to undergo CRS (interval debulking or recurrent surgery) followed by HIPEC with oxaliplatin (460 mg/m2) for 30 min.
  • No patient received adjuvant chemotherapy after HIPEC.
  • Median peritoneal cancer index at surgery was 6 (range: 1-18).
  • CONCLUSION: HIPEC without adjuvant chemotherapy is both feasible and safe, but with a high rate of grade 3-5 toxicity.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hyperthermia, Induced / methods. Organoplatinum Compounds / administration & dosage. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Combined Modality Therapy / mortality. Disease Progression. Feasibility Studies. Female. Humans. Infusions, Parenteral. Length of Stay. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20202920.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


2. Samaritani R, Corrado G, Vizza E, Sbiroli C: Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer; 2007;7:65
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
  • BACKGROUND: Evaluation of the clinical efficacy and tolerance of metronomic chemotherapy as salvage therapy in a young patient with advanced, platinum resistant, ovarian carcinoma and bad performance status.
  • CASE PRESENTATION: We tried palliative chemotherapy with daily low dose oral cyclophosphamide with a patient suffering from stage IIIC ovarian cancer that responded to daily cyclophosphamide (CTX) after no response to chemotherapy with paclitaxel and carboplatin as first line and progression after second line with topotecan.
  • The progression-free survival time on daily low dose oral cyclophosphamide treatment was 65 months without side effects.
  • She was well during the chemotherapy and lived a normal working and social life.
  • CONCLUSION: We think that use of low dose of oral CTX should be investigated further as a strategy against tumour progression after standard chemotherapy in patients who are platinum resistant with poor performance status.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy. Palliative Care. Salvage Therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Colonic Neoplasms / complications. Colonic Neoplasms / secondary. Colonic Neoplasms / surgery. Colostomy. Disease-Free Survival. Drug Administration Schedule. Drug Evaluation. Drug Resistance, Neoplasm. Epoetin Alfa. Erythropoietin / therapeutic use. Fatal Outcome. Female. Follow-Up Studies. Hemorrhage / etiology. Humans. Intestinal Obstruction / etiology. Karnofsky Performance Status. Laparotomy. Ovariectomy. Paclitaxel / administration & dosage. Peritoneal Neoplasms / secondary. Recombinant Proteins. Topotecan / administration & dosage. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / secondary. Vitamins / therapeutic use

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. EPOETIN ALFA .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Apr;105(8):R15-24 [10772661.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):427-36 [11693902.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):12-5 [11863092.001]
  • [Cites] Lancet Oncol. 2001 Dec;2(12):733-40 [11902515.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2731-5 [12019144.001]
  • [Cites] Int J Oncol. 2002 Jul;21(1):179-86 [12063566.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Nov;2(11):562-77 [16270097.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12917-22 [14561896.001]
  • [Cites] Minerva Ginecol. 2004 Feb;56(1):81-9 [14973412.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):939-52 [15557593.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):916-23 [15907981.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6938-43 [12460910.001]
  • (PMID = 17433113.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Vitamins; 11096-26-7 / Erythropoietin; 64FS3BFH5W / Epoetin Alfa; 7M7YKX2N15 / Topotecan; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1863429
  •  go-up   go-down


3. Zivanovic O, Sima CS, Iasonos A, Hoskins WJ, Pingle PR, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS: The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. Gynecol Oncol; 2010 Mar;116(3):351-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.
  • OBJECTIVE: Our objective was to analyze the effect of surgical outcome on progression-free survival (PFS) and overall survival (OS) of patients with advanced ovarian carcinoma stratified by the initial presence and volume of upper abdominal disease cephalad to the greater omentum (UAD) found at the time of exploration.
  • METHODS: We evaluated all patients with FIGO stage IIIC ovarian carcinoma who underwent primary cytoreduction followed by platinum-based chemotherapy at our institution between January 1989 and December 2006.
  • The effect of surgical outcome was investigated using a time-to-event analysis.
  • The findings support the management strategy of maximizing surgical efforts with increasing tumor burden in patients with stage IIIC ovarian cancer.
  • [MeSH-major] Omentum / pathology. Omentum / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Proportional Hazards Models. Survival Rate. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20022092.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds
  • [Other-IDs] NLM/ NIHMS774763; NLM/ PMC4843127
  •  go-up   go-down


Advertisement
4. Muramatsu T, Yamashita E, Takahashi K, Sugiyama T, Tsukada H, Kondo A, Hirasawa T, Murakami M, Yasuda S, Mikami M: Usefulness of combined PET/CT for patient with epithelial ovarian cancer showing recurrence based on tumor marker CA125. Tokai J Exp Clin Med; 2007 Mar;32(1):23-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of combined PET/CT for patient with epithelial ovarian cancer showing recurrence based on tumor marker CA125.
  • We report the case of a 41-year-old patient with epithelial ovarian cancer of stage IIIc.
  • One year and nine months after completion of chemotherapy performed after surgery, the level of the tumor marker CA125 began to increase gradually.
  • Conventional computed tomography (CT) and magnetic resonance imaging (MRI) were performed, but the recurrence site could not be determined clearly.
  • However, combined positron emission tomography/computed tomography (PET/CT) revealed a metastasis in the right external iliac lymph node.
  • This allowed commencement of chemotherapy at an early recurrent stage and subsequently the level of CA125 showed a significant decrease.
  • [MeSH-major] Biomarkers, Tumor / metabolism. CA-125 Antigen / metabolism. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Lymphatic Metastasis / diagnosis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / prevention & control. Neoplasms, Glandular and Epithelial / therapy. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Ovarian Neoplasms / prevention & control. Ovarian Neoplasms / therapy. Recurrence

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319052.001).
  • [ISSN] 2185-2243
  • [Journal-full-title] The Tokai journal of experimental and clinical medicine
  • [ISO-abbreviation] Tokai J. Exp. Clin. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; Ovarian epithelial cancer
  •  go-up   go-down


5. Zivanovic O, Sima CS, Iasonos A, Bell-McGuinn KM, Sabbatini PJ, Leitao MM, Levine DA, Gardner GJ, Barakat RR, Chi DS: Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol; 2009 Nov;115(2):209-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.
  • OBJECTIVE: To analyze whether serum CA-125 response to cytoreductive surgery before initiation of postoperative chemotherapy is associated with progression-free survival (PFS) in patients with stage IIIC ovarian carcinoma.
  • METHODS: We included consecutive patients with paired pre- and postoperative CA-125 measurements who underwent primary cytoreductive surgery followed by platinum-based chemotherapy between 1989 and 2006.
  • The association of perioperative CA-125 changes with PFS was investigated using a time-to-event analysis.
  • A Cox proportional hazards model was fit using clinical, surgical, and postoperative treatment characteristics.
  • CONCLUSION: Perioperative serum CA-125 changes are strongly associated with the risk of relapse in patients with optimally resected stage IIIC disease.
  • [MeSH-major] CA-125 Antigen / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Proportional Hazards Models. Recurrence

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 May 1;97(9):2187-95 [12712470.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):307-12 [3164697.001]
  • [Cites] Gynakol Rundsch. 1990;30 Suppl 1:210-1 [2079273.001]
  • [Cites] Eur J Cancer. 1993;29A(7):966-71 [8499150.001]
  • [Cites] Gynecol Oncol. 1995 Jul;58(1):42-7 [7789889.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1545-51 [8622070.001]
  • [Cites] Ann Oncol. 1996 Apr;7(4):361-4 [8805927.001]
  • [Cites] N Engl J Med. 1996 Nov 7;335(19):1413-6 [8875917.001]
  • [Cites] Gynecol Oncol. 1996 Nov;63(2):234-7 [8910633.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):47-50 [15598937.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1454-8 [16549840.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1234-8 [16766592.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):195-8 [16595148.001]
  • [Cites] Gynecol Oncol. 2007 Jan;104(1):176-80 [16996584.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5284-93 [18854563.001]
  • [Cites] Cancer. 2009 Mar 1;115(5):1028-35 [19156927.001]
  • [Cites] JAMA. 2000 May 3;283(17):2260-5 [10807385.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5 [10995813.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4054-7 [11600607.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):487-8 [15026475.001]
  • (PMID = 19664812.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Organoplatinum Compounds
  • [Other-IDs] NLM/ NIHMS523348; NLM/ PMC3870341
  •  go-up   go-down


6. Zylberberg B, Dormont D, Janklewicz S, Darai E, Bretel JJ, Poncelet C, Guillet JL, Madelenat P: Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. Eur J Gynaecol Oncol; 2001;22(1):40-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer.
  • DESIGN: The aim of this study was to determine the effect of intraperitoneal (i.p.) neo-adjuvant immunochemotherapy, followed by secondary interval cytoreduction in bulky ovarian carcinoma, considered inoperable at first exploratory laparotomy.
  • PATIENTS AND METHODS: From 1980 to 1996, 13 naive patients with stage IIIc ovarian cancer underwent an initial laparotomy.
  • The interval secondary cytoreduction was started either when the patients seemed to be in complete remission or after a minimum of 4 courses of chemotherapy if the patients' results were stagnant or deteriorated.
  • [MeSH-major] Carcinoma, Endometrioid / therapy. Cystadenocarcinoma, Serous / therapy. Neoadjuvant Therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunotherapy. Injections, Intraperitoneal. Injections, Intravenous. Middle Aged. Neoplasm Staging. Reoperation. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11321492.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Kobayashi K, Fujimoto S, Takahashi M, Mutou T, Toyosawa T, Ohtsuka Y, Ogasawara T: [A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1726-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion].
  • Intraperitoneal hyperthermic chemoperfusion (IHCP) was performed on a stage IIIc ovarian cancer patient with massive ascites who had been chemotherapy resistant.
  • Complete response was observed after the treatment.
  • A 59-year-old woman with advanced ovarian cancer complained of massive refractory ascites after 2 years' history of chemotherapy.
  • Soon after the treatment, the massive ascites disappeared and CA125 level decreased to normal.
  • The patient remained free of ascites for 14 months after the treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascitic Fluid / therapy. Cystadenocarcinoma, Serous / therapy. Drug Resistance, Neoplasm. Hyperthermia, Induced. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619504.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Oksefjell H, Sandstad B, Tropé C: Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001. Eur J Gynaecol Oncol; 2007;28(4):256-62
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001.
  • BACKGROUND: The aim of this study was to evaluate the treatment of FIGO Stage IIIC patients who were primarily treated completely or partially at the Norwegian Radium Hospital (NRH) during a 15-year period in order to discover possibilities for improvement of prognosis of advanced ovarian cancer.
  • MATERIALS AND METHOD: A retrospective study based on record information from all patients with epithelial ovarian cancer Stage IIIC treated at NRH from 1985-2000, in total 776 patients.
  • RESULTS: We found age, amount of residual tumour after surgery for primary treatment and type of chemotherapy to be the most significant prognostic factors for overall survival.
  • We believe that further centralisation of primary surgery for advanced ovarian cancer can contribute to a better prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cancer Care Facilities. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Longitudinal Studies. Middle Aged. Norway. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713088.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Shimura K, Shimazaki C, Okano A, Hatsuse M, Okamoto A, Takahashi R, Hirai H, Sumikuma T, Ashihara E, Inaba T, Fujita N, Yasuda J, Nakagawa M: [Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer]. Rinsho Ketsueki; 2001 Feb;42(2):99-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer].
  • A 40-year-old woman, who had suffered from AML (M1) in 1983, developed ovarian cancer (stage IIIc) in December 1996 after long-term remission.
  • She underwent surgical resection of the cancer, 10 courses of standard chemotherapy and tandem PBSCT (total dose: CBDCA 6,750 mg, CDDP 200 mg, CPA 16,000 mg, THP-ADR 450 mg).
  • After receiving the last course of chemotherapy in June 1998, she was referred to our hospital in September 1998 because of pancytopenia.
  • The patient was diagnosed as having AML (M5a), and received induction therapy consisting of IDR and Ara-C, which led to complete remission.
  • As she had not received etoposide, this case was thought to have been therapy-related leukemia due to the platinum agents used for treating the ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / adverse effects. Cisplatin / adverse effects. Doxorubicin / analogs & derivatives. Leukemia, Myeloid / etiology. Neoplasms, Second Primary / etiology. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11280924.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 11
  •  go-up   go-down


10. Yamakawa H, Ariga H, Enomoto A, Netsu S, Suzuki Y, Konno R: Meningeal dissemination from an ovarian carcinoma with effective response to intrathecal chemotherapy. Int J Clin Oncol; 2009 Oct;14(5):447-51
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal dissemination from an ovarian carcinoma with effective response to intrathecal chemotherapy.
  • Meningeal dissemination is rare in the clinical course of ovarian carcinoma, and its prognosis is poor.
  • Although it is treated by the intrathecal administration of methotrexate (MTX) and/or total brain irradiation, these treatments are usually ineffective.
  • We report a 58-year-old woman with stage IIIc ovarian cancer who had received nine courses of adjuvant chemotherapy after surgery.
  • BT) maintenance therapy.
  • However, results of head computed tomography (CT), head magnetic resonance imaging, and electroencephalogram were normal.
  • Meningeal dissemination of the ovarian cancer was diagnosed, as adenocarcinoma cells were found by cerebrospinal fluid (CSF) cytology.
  • We started chemotherapy with intrathecal injections of MTX and hydrocortisone acetate.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Meningeal Carcinomatosis / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Electroencephalography. Female. Humans. Hydrocortisone / administration & dosage. Hydrocortisone / analogs & derivatives. Injections, Spinal. Magnetic Resonance Imaging. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Spinal Puncture. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):196-204 [15102345.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):201-8 [16941075.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1655-62 [3309199.001]
  • [Cites] Gynecol Oncol. 1984 May;18(1):119-24 [6714801.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1315-23 [8608509.001]
  • [Cites] Surg Neurol. 2005 Jan;63(1):52-5; discussion 55 [15639526.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Int J Clin Oncol. 2001 Jun;6(3):157-62 [11706787.001]
  • [Cites] Jpn J Clin Oncol. 2003 Dec;33(12):608-12 [14769837.001]
  • [Cites] J Neurooncol. 1992 May;13(1):81-9 [1613540.001]
  • [Cites] Neurosurgery. 2000 Jul;47(1):49-54; discussion 54-5 [10917346.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3394-402 [10589750.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):773-86 [8922190.001]
  • (PMID = 19856055.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3X7931PO74 / hydrocortisone acetate; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Watanabe A, Shimada M, Kigawa J, Iba T, Oishi T, Kanamori Y, Terakawa N: The benefit of chemotherapy in a patient with multiple brain metastases and meningitis carcinomatosa from ovarian cancer. Int J Clin Oncol; 2005 Feb;10(1):69-71
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The benefit of chemotherapy in a patient with multiple brain metastases and meningitis carcinomatosa from ovarian cancer.
  • We report on a 45-year-old patient with stage IIIc ovarian cancer, multiple brain metastases, and meningitis carcinomatosa.
  • After three courses of initial chemotherapy, consisting of docetaxel and carboplatin, the patient underwent interval cytoreductive surgery, consisting of hyster-ectomy, bilateral salpingo-oophorectomy, omentectomy, appendectomy, and retroperitoneal lymphadenectomy.
  • Then five courses of the same chemotherapy were given as adjuvant treatment.
  • At the completion of the primary therapy, she achieved a complete remission.
  • Ten months after the completion of the initial treatment, multiple brain metastases with meningitis carcinomatosa were detected.
  • After four courses of the same chemotherapy, she again had a complete response, confirmed by cranial enhanced magnetic resonance imaging (MRI), and she felt well, with relief from the debilitating neurologic symptoms for 4 months.
  • Chemotherapy can help to prolong life for some patients with multiple brain metastases and meningitis carcinomatosa from ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma / drug therapy. Carcinoma / secondary. Meningitis / drug therapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology


12. Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, Kim YT, Nam JH: Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):101-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy.
  • This study reviews the clinical outcome and prognosis of patients with malignant mixed müllerian tumors (MMMTs) of the ovary treated with optimal cytoreductive surgery, leaving no residual disease, and platinum-based chemotherapy.
  • Ten patients diagnosed with MMMT of the ovary after complete surgical staging from February 1993 to February 2004 at Asan Medical Center in Korea were studied retrospectively.
  • Seven patients received ifosfamide/cisplatin chemotherapy, and the remaining three patients received other platinum-based combination chemotherapy.
  • Demographic data, pathologic findings, treatments, and survival time were reviewed.
  • Of the ten patients, two were scored at FIGO stage IIC, seven were at stage IIIC, and one was at stage IV.
  • The median survival time of all ten patients was 46 months.
  • Platinum-based combination chemotherapy after optimal cytoreductive surgery may be effective in the treatment of ovarian MMMT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Mixed Tumor, Mullerian / drug therapy. Mixed Tumor, Mullerian / mortality. Ovarian Neoplasms / mortality. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Probability. Retrospective Studies. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445618.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Zhao XD, Zhang Y, He SR, Yang L: [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma]. Ai Zheng; 2005 Dec;24(12):1542-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
  • BACKGROUND & OBJECTIVE: The first-line adjuvant chemotherapy regimens of ovarian cancer mainly include TC (paclitaxel combined with carboplatin) and PC (cisplatin combined with cyclophosphamide) protocols.
  • This study was to investigate the correlation of P53 expression to treatment outcome of ovarian cancer patients received the above 2 protocols, and explore the predictive value of P53 expression in selecting chemotherapy regimen.
  • METHODS: Records of 53 patients with advanced epithelial ovarian cancer (stage IIIc), treated with TC or PC regimen, were analyzed retrospectively.
  • CONCLUSIONS: P53 detection may play a role in selecting first-line chemotherapy for advanced epithelial ovarian cancer patients: TC regimen is preference for P53-positive patients, PC regimen may be a choice for P53-negative patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Middle Aged. Paclitaxel / administration & dosage. Predictive Value of Tests. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351810.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Rose PG, Drake R, Braly PS, Bell MC, Wenham RM, Hines JH, Alvarez-Secord A, Soltes-Rak E, Childs BH, Herzog TJ: Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol; 2009 May 20;27(15_suppl):5546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
  • : 5546 Background: Objectives are to estimate efficacy and safety of a novel taxane/platinum chemotherapy doublet in combination with bevacizumab (B), as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube (FT), after initial debulking surgery.
  • Subjects were treated with 6 cycles of oxaliplatin (85 mg/m2), docetaxel (75 mg/m2) and B (15 mg/kg) Q3W, followed by maintenance B (15 mg/kg Q3W) to complete one year of therapy.
  • Tumors were mostly ovary as primary site (84%), poorly differentiated (65%), serous adenocarcinoma pathology (73%) and FIGO stage IIIC (68.2%) or IV (14.6%).
  • 95 (86%) of subjects had completed the chemotherapy cycles with 87 of the 95 having started on the B-only maintenance cycles.
  • 85 (77%) subjects have stopped study treatment [including 33 completed study treatment, 29 disease progression, 15 adverse event (AE), 8 other reasons].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962510.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Oksefjell H, Sandstad B, Trope C: Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival. Eur J Gynaecol Oncol; 2006;27(3):209-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival.
  • BACKGROUND: Maximum cytoreduction at primary surgery has been found to be one of the strongest prognostic factors for survival of ovarian cancer.
  • The aim of the study was to investigate the influence of hospital level (primary vs secondary care centre), number and timing of surgery and chemotherapy on how radical the surgery was at primary treatment of epithelial ovarian cancer Stage IIIC.
  • MATERIAL AND METHODS: A retrospective study based on record information from all patients with epithelial ovarian cancer Stage IIIC treated at the Norwegian Radium Hospital (NRH) 1985-2000, in total 776, subdivided into four groups:.
  • 2) local primary surgery, no direct re-operation, but interval debulking after 3-4 courses of chemotherapy at NRH;.
  • Lymph node biopsies at re-operation in early stages and upgrading of stage where necessary were registered.
  • The treatment group was an independent prognostic factor for overall, but not for progression-free survival.
  • Most lymph node biopsies were performed during the last period and 28% were upgraded from Stage I and II to IIIC.
  • More patients were referred for primary surgery at NRH during the last 5-year period during which overall survival and time to progression were significantly better.
  • [MeSH-major] Carcinoma / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800244.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Motl SE, Fausel C: Recurring chemotherapy-associated alopecia areata: case report and literature review. Pharmacotherapy; 2003 Jan;23(1):104-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurring chemotherapy-associated alopecia areata: case report and literature review.
  • A 52-year-old woman with stage IIIC ovarian cancer and stage IA uterine cancer experienced recurring alopecia areata of her eyebrows, eyelashes, arms, legs, and pubic area beginning 5 months after completing chemotherapy with paclitaxel and carboplatin.
  • Alopecia is a well-recognized adverse event associated with chemotherapy; however, to our knowledge, this cyclic pattern of alopecia has not been reported in a patient with cancer.
  • Our report of a cancer survivor who experienced cyclic alopecia areata indicates that this condition may be related to autoimmune changes instigated by chemotherapy.
  • [MeSH-major] Alopecia Areata / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects

  • Genetic Alliance. consumer health - Alopecia Areata.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12523468.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 21
  •  go-up   go-down


17. Kuhn W, Rutke S, Späthe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H: Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer; 2001 Nov 15;92(10):2585-91
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
  • BACKGROUND: Patients with advanced ovarian carcinoma of International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC should be treated by radical surgical tumor debulking with the goal of complete tumor resection.
  • Prolonged median survival can be achieved in those patients entirely free of tumor after surgery by the administration of postsurgical platinum/taxane-based chemotherapy regimens.
  • Different therapy approaches should be utilized to improve prognosis in these patients.
  • Neoadjuvant chemotherapy could induce "downstaging" of the tumor and thus improve operability.
  • Here, evidence of large ascites volume (>500 mL) can be used to identify those patients who could benefit from neoadjuvant chemotherapy.
  • METHODS: In a prospective, nonrandomized Phase II study, 31 patients with advanced FIGO Stage IIIC ovarian carcinoma and large ascites volume (>500 mL) received 3 cycles of platinum/taxane-based combination chemotherapy, followed by tumor debulking surgery and 3 additional cycles of platinum/taxane-based combination chemotherapy.
  • During the same period, 32 patients with advanced FIGO Stage IIIC ovarian carcinoma and large ascites volume (>500 mL) received conventional therapy (tumor debulking surgery followed by 6 cycles of platinum/taxane-based combination chemotherapy).
  • RESULTS: The tumor resection rate in the patient group receiving neoadjuvant chemotherapy was significantly higher (P = 0.04) than that of the conventionally treated group; the median survival time of 42 months versus 23 months also was significantly longer (P = 0.007).
  • Time spent in surgery, blood transfusion requirements, morbidity, and mortality during surgery were not significantly different.
  • CONCLUSIONS: Patients with advanced ovarian carcinoma of FIGO Stage IIIC who will benefit only marginally from conventional therapy can be identified by evidence of large ascites volume.
  • Higher tumor resection rates and longer median survival can be achieved in these patients by the use of neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Postoperative Complications. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745193.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Komiyama S, Mizusawa Y, Onouchi M, Takehara K, Suzuki A, Mikami M: Effective weekly docetaxel for recurrent ovarian cancer: A case report. Int J Gynecol Cancer; 2003 Sep-Oct;13(5):683-6
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective weekly docetaxel for recurrent ovarian cancer: A case report.
  • We experienced a case of recurrent ovarian cancer that responded to weekly docetaxel.
  • The patient had stage IIIC ovarian cancer (poorly differentiated serous adenocarcinoma).
  • After initial remission was achieved by chemotherapy with paclitaxel and carboplatin plus cytoreductive surgery, the disease recurred and irinotecan therapy achieved temporary remission.
  • During maintenance therapy with oral etoposide, the disease recurred again.
  • We then tried five courses of weekly docetaxel therapy and it successfully controlled the disease.
  • The progression-free survival time on weekly docetaxel treatment is now 7 months and the toxicity was extremely low.
  • This patient demonstrates the effectiveness of weekly docetaxel as salvage chemotherapy for recurrent ovarian cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Cystadenocarcinoma, Serous / therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / therapy. Taxoids / administration & dosage
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Staging. Palliative Care

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14675355.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


19. Terauchi F, Nishi H, Moritake T, Kobayashi Y, Nagashima T, Onodera T, Fujito A, Nakayama D, Isaka K: Prognostic factor on optimal debulking surgery by maximum effort for stage IIIC epithelial ovarian cancer. J Obstet Gynaecol Res; 2009 Apr;35(2):315-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factor on optimal debulking surgery by maximum effort for stage IIIC epithelial ovarian cancer.
  • OBJECTIVES: The aim of this study was to assess the prognostic factor of radical surgery in patients with stage IIIc ovarian cancer.
  • A worse prognosis was obtained in the more-than-4-weeks-delayed postoperative chemotherapy group, assessing poor-outcome cases in the OPCS group.
  • A case that required more than three colon resections was the significant factor for the delay of postoperative chemotherapy.
  • CONCLUSIONS: OPCS should be performed with maximum effort to improve the prognosis of stage IIIc ovarian cancer.
  • We should avoid any delay in starting postoperative chemotherapy.
  • In cases that require more than three colon resections, it seems that 'perioperative management' should be reconsidered and that priority should be given to postoperative management so that chemotherapy can be started soon after the operation.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / surgery. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708178.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, Lhommé C, Duvillard P, Castaigne D: Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg; 2003 Dec;197(6):955-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
  • BACKGROUND: Results of IDS (after three to four courses of induction chemotherapy) were compared with PDS followed by chemotherapy in patients treated for advanced stage ovarian cancer (stage IIIC or IV).
  • STUDY DESIGN: A retrospective study was done on a group of 57 patients who underwent IDS (because of an unresectable tumor) compared with a group of 28 patients treated with PDS (for resectable disease) followed by chemotherapy.
  • All patients were treated between 1996 and 2001 by the same team of surgeons and received the same regimen of chemotherapy (platinum based plus paclitaxel).
  • CONCLUSIONS: Survival rates were similar in patients with advanced stage ovarian cancer who underwent IDS or PDS.
  • IDS can be safely used in unresectable advanced stage ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Gynecologic Surgical Procedures / methods. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Drug Administration Schedule. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Paclitaxel / administration & dosage. Platinum Compounds / administration & dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14644284.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Platinum Compounds; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Chan JK, Loizzi V, Manetta A, Berman ML: Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol Oncol; 2004 Jan;92(1):368-71
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral altretamine used as salvage therapy in recurrent ovarian cancer.
  • BACKGROUND: Altretamine has reported efficacy in the treatment of recurrent ovarian cancer following platinum-based therapy.
  • This report presents the cases of two long-term survivors with recurrent ovarian cancer given oral altretamine.
  • CASES: Two patients diagnosed with stage IIIC ovarian cancer underwent optimal cytoreductive surgery.
  • Both women were subsequently treated with platinum-based chemotherapy.
  • One had persistent cancer documented 2 months post therapy, while the other was disease-free for 22 months before recurring.
  • Each of these women achieved a prolonged response to third-line altretamine therapy, and one of whom was disease-free for 4 years and the other remains disease-free over 7 years following initiation of salvage therapy.
  • [MeSH-major] Altretamine / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Female. Humans. Middle Aged. Salvage Therapy

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALTRETAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14751188.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q8BIH59O7H / Altretamine
  •  go-up   go-down


22. Zylberberg B, Dormont D, Madelenat P, Daraï E: First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer. Eur J Gynaecol Oncol; 2004;25(3):327-32
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
  • OBJECTIVES: To determine the feasibility, toxicity and efficacy of a first-line combination of intraperitoneal (i.p.) paclitaxel and cisplatin and intravenous (i.v.) ifosfamide in untreated patients with Stage IIIc ovarian cancer after cytoreduction or biopsies only.
  • Ten cycles of chemotherapy were planned by both routes.
  • RESULTS: Twenty-one (81%) of the 26 patients were in complete clinical remission (CCR) at the time of second-look surgery.
  • CONCLUSION: This study has demonstrated the feasibility, moderate toxicity and efficacy of first-line intraperitoneal paclitaxel-cisplatin chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Carcinoma / drug therapy. Carcinoma / mortality. Carcinoma / pathology. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cisplatin / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Disease-Free Survival. Drug Administration Schedule. Female. France. Humans. Ifosfamide / administration & dosage. Infusions, Intravenous. Infusions, Parenteral. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15171311.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


23. Kawashima T, Murakami H, Kanamori T, Nakamura Y: [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy]. Gan To Kagaku Ryoho; 2007 Mar;34(3):461-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
  • An exploratory laparotomy was performed and stage IIIc ovarian cancer was diagnosed.
  • Six courses of docetaxel-carboplatin (DJ) chemotherapy were administered; however, the lesion was assessed as progressive disease (PD), and 24 courses of weekly paclitaxel were then administered.
  • Weekly paclitaxel was not effective this time, and the lesion was assessed as PD.
  • The patient therefore received treatment with irinotecan and cisplatin (CPT-11+CDDP).
  • These drugs have different mechanisms of action.
  • These results suggest that CPT-11+CDDP may be effective against recurrent ovarian cancer, which is difficult to treat due to its resistance to platinum drugs and taxane drugs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Drug Resistance, Neoplasm. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Bridged Compounds / pharmacology. CA-125 Antigen / blood. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Drug Administration Routes. Female. Humans. Laparotomy. Paclitaxel / pharmacology. Remission Induction. Taxoids / pharmacology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353644.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bridged Compounds; 0 / CA-125 Antigen; 0 / Taxoids; 1605-68-1 / taxane; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


24. Hasegawa T, Nakashima A, Ishimaru M, Shima T, Hidaka T, Saito S: Carcinomatous meningitis associated with ovarian cancer complicated by SIADH. Gan To Kagaku Ryoho; 2010 Apr;37(4):739-42
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomatous meningitis associated with ovarian cancer complicated by SIADH.
  • We experienced a case of carcinomatous meningitis originating from stage IIIc ovarian cancer complicated by syndrome of inappropriate antidiuretic hormone secretion (SIADH).
  • A 51-year-old woman had been treated with multiple chemotherapy regimens after an initial operation for ovarian cancer.
  • During the last chemotherapy regimen, she suffered headache, mood changes and ataxia.
  • Carcinomatous meningitis complicated by SIADH was diagnosed and treatment for hyponatremia and whole brain radiotherapy were performed; however, she died two weeks after the radiation therapy.
  • [MeSH-major] Inappropriate ADH Syndrome / complications. Meningeal Carcinomatosis / complications. Ovarian Neoplasms / complications
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Treatment Failure

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414039.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Ceelen WP, Påhlman L, Mahteme H: Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res; 2007;134:195-214
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamic aspects of intraperitoneal cytotoxic therapy.
  • The superiority of combined ip and intravenous chemotherapy over intravenous chemotherapy alone has been established in randomized trials in stage IIIc ovarian cancer patients.
  • Intraoperative ip cytotoxic therapy results in a definite pharmacological advantage, since high peritoneal concentrations are achieved with limited systemic absorption.
  • Preclinical models show that direct penetration into tumour tissue is limited to a few millimeters.
  • Furthermore, the limited exposure time of intraoperative chemoperfusion could limit cytotoxic activity despite high local concentrations.
  • Pharmacodynamic aspects of HIPEC needing further preclinical study-including mathematical modeling - are the establishment of tumour tissue penetration of the newer agents and its relation to hyperthermia, the definition of the relative contribution of direct penetration versus vascular supply by absorbed drug, and the efficacy of combined ip and intravenous regimens.
  • Ultimately, however, randomised trials of ip chemotherapy with surgery will have to provide the evidence base to further build upon.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Infusions, Parenteral / methods. Neoplasms / metabolism. Peritoneum / metabolism
  • [MeSH-minor] Animals. Humans. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633055.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 79
  •  go-up   go-down


26. Weiss SJ, Smith T, Laurin E, Wisner DH: Spontaneous splenic rupture due to subcutaneous heparin therapy. J Emerg Med; 2000 May;18(4):421-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous splenic rupture due to subcutaneous heparin therapy.
  • Her past medical history included multiple DVT, pulmonary emboli, and ovarian cancer stage III-C with known ascites.
  • This case illustrates both a previously undescribed complication of s.c. heparin therapy and a failure of ultrasound diagnosis.
  • [MeSH-major] Anticoagulants / adverse effects. Emergency Treatment / methods. Heparin / adverse effects. Splenic Rupture / chemically induced. Venous Thrombosis / drug therapy
  • [MeSH-minor] Ascites / complications. Diagnosis, Differential. Female. Hematocrit. Humans. Middle Aged. Ovarian Neoplasms / complications. Peritonitis / diagnosis. Pulmonary Embolism / complications. Rupture, Spontaneous. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10802418.001).
  • [ISSN] 0736-4679
  • [Journal-full-title] The Journal of emergency medicine
  • [ISO-abbreviation] J Emerg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anticoagulants; 9005-49-6 / Heparin
  •  go-up   go-down


27. Rochet N, Sterzing F, Jensen A, Dinkel J, Herfarth K, Schubert K, Eichbaum M, Schneeweiss A, Sohn C, Debus J, Harms W: Helical tomotherapy as a new treatment technique for whole abdominal irradiation. Strahlenther Onkol; 2008 Mar;184(3):145-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helical tomotherapy as a new treatment technique for whole abdominal irradiation.
  • PURPOSE: To describe a new intensity-modulated radiotherapy (IMRT) technique using helical tomotherapy for whole abdominal irradiation (WAI) in patients with advanced ovarian cancer.
  • MATERIAL AND METHODS: A patient with radically operated ovarian cancer FIGO stage IIIc was treated in a prospective clinical trial with WAI to a total dose of 30 Gy in 1.5-Gy fractions as an additional therapy after adjuvant platinum-based chemotherapy.
  • PTV was adapted according to breathing motion as detected in a four-dimensional respiratory-triggered computed tomography (4D-CT).
  • Inverse treatment planning was done with the Hi-Art tomotherapy planning station.
  • Daily control of positioning accuracy was performed with megavoltage computed tomography (MV-CT).
  • Mean liver dose was 21.57 Gy and mean kidney doses were 9.75 Gy and 9.14 Gy, respectively.
  • Treatment could be performed in 18.1 min daily and no severe side effects occurred.
  • [MeSH-major] Abdomen / radiation effects. Ovarian Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Algorithms. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Bone Marrow / radiation effects. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Image Processing, Computer-Assisted. Kidney / radiation effects. Liver / radiation effects. Middle Aged. Neoplasm Staging. Ovary / pathology. Paclitaxel / administration & dosage. Paclitaxel / therapeutic use. Prospective Studies. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Time Factors. Tomography, Spiral Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18330510.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


28. Ang D, Ng KY, Tan HK, Chung AY, Yew BS, Lee VK: Ovarian carcinoma presenting with isolated contralateral inguinal lymph node metastasis: a case report. Ann Acad Med Singapore; 2007 Jun;36(6):427-30
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinoma presenting with isolated contralateral inguinal lymph node metastasis: a case report.
  • INTRODUCTION: Ovarian carcinoma usually presents at an advanced stage with diffuse intraabdominal manifestations.
  • A computed tomography (CT) scan showed an enlarged left ovarian lesion (9.0 x 6.4 cm).
  • TREATMENT AND OUTCOME: Laparotomy with total hysterectomy, bilateral salpingo-oophrectomy and partial omentectomy were performed.
  • Histology confirmed left ovarian adenocarcinoma, consistent with the earlier histology of the right inguinal lymph node.
  • Postoperatively, the patient received adjuvant chemotherapy for treatment of FIGO Stage IIIc ovarian carcinoma and is clinically disease free 13 months after surgery.
  • CONCLUSIONS: Ovarian cancer presenting with inguinal lymph node metastases is uncommon.
  • Ovarian cancer which manifests solely as a contralateral inguinal lymph node metastasis has not been previously reported.
  • This case illustrates a rare presentation of ovarian carcinoma, and underscores the need to consider ovarian carcinoma in the differential diagnosis of women with inguinal lymphadenopathy.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Female. Groin. Humans. Lymphatic Metastasis. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597969.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


29. Kelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE: Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol; 2004 Dec;95(3):469-73
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
  • OBJECTIVE: The coexistence of minimal uterine disease and extrauterine metastases is common in patients with uterine papillary serous carcinoma (UPSC).
  • The purpose of this study was to evaluate different therapeutic options in surgically staged patients.
  • RESULTS: Twenty-three (45%) cases were International Federation of Gynecology and Obstetrics (FIGO) stage IA, seven (15%) were stage IIIA, one (2%) was stage IIIC, and nine (18%) stage IV.
  • Additionally, 11 of these 51 patients (21%) were diagnosed with two cancers: a stage IA UPSC and concomitant advanced stage serous cancer of the ovary, fallopian tube, or peritoneum.
  • Stage IA patients with no cancer in the hysterectomy specimen (defined as no residual uterine disease) had no recurrences (n = 10) regardless of treatment.
  • There was a trend toward increased survival in stage IA patients with residual uterine disease who were treated with chemoradiation (concomitant vaginal brachytherapy and platinum-based chemotherapy).
  • All patients with advanced stage UPSC (stage IIIC or IV or two primary cancers) did poorly regardless of treatment.
  • CONCLUSION: Our findings suggest that stage IA patients with no residual uterine disease may be observed.
  • Stage IA patients with residual uterine disease may benefit from chemoradiation.
  • More effective treatment needs to be identified for advanced stage UPSC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Papillary / therapy. Cystadenocarcinoma, Serous / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Brachytherapy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15581948.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down


30. Takeyama S, Aoki Y, Kamimura N, Suzuki M, Tanaka K: Retrieval of intraperitoneal Penrose drain under transvaginal endoscopic guidance. Gynecol Oncol; 2006 Aug;102(2):391-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 49-year-old woman with the International Federation of Gynecology and Obstetrics (FIGO) stage IIIc ovarian cancer underwent bilateral salpingo-oophorectomy, total hysterectomy, partial omentectomy, and pelvic and para-aortic lymph nodes removal.
  • She went home on the 9th day after the initial operation and started to receive postoperative adjuvant chemotherapy on the 17th day.
  • [MeSH-major] Drainage / instrumentation. Foreign Bodies / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Foreign Bodies.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16542713.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut HV, Mancuso S, Scambia G: Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology; 2003;65(4):316-22
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients.
  • OBJECTIVES: To report the results of neoadjuvant chemotherapy (NACT) and the impact of interval debulking surgery (IDS) on clinical outcomes of patients considered unresectable at primary surgery.
  • METHODS: Retrospective analysis was carried out on 73 consecutive stage IIIc ovarian cancer patients treated with platinum-based NACT followed by IDS.
  • Their clinical outcomes were compared with those of 111 consecutive stage IIIc ovarian cancer patients treated with primary cytoreduction followed by platinum-based adjuvant chemotherapy.
  • RESULTS: Patients who underwent successful IDS had a more favorable prognosis than those who did not in terms of time to progression (TTP) (p = 0.00001), and overall survival (OS) (p = 0.0001).
  • CONCLUSIONS: NACT followed by successful IDS can achieve good results in terms of survival outcomes in a high percentage of chemoresponsive IIIc ovarian cancer patients classified as unresectable at primary surgery.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy / methods
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Life Tables. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14707451.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds
  •  go-up   go-down






Advertisement